NCT04862338View on ClinicalTrials.gov

Pharmacodynamics and Tolerance of Nicotinamide Mononucleotide (NMN, 400mg/Day) in Healthy Adults

NACompletedINTERVENTIONAL

Enrollment

17

Participants

Timeline

Start Date

April 26, 2021

Primary Completion Date

September 8, 2021

Study Completion Date

April 4, 2022

Conditions

Healthy Volunteers

Interventions

DIETARY_SUPPLEMENT

Nicotinamide mononucleotide (NMN-C)

Nicotinamide mononucleotide (NMN-C) at 400 mg/day for 28 days in total

Trial Locations (1)

21000

Biomed 21, Dijon

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

CEN Biotech

INDUSTRY

collaborator

LGD

INDUSTRY

lead

Seneque SA

INDUSTRY